疗效难达预期,百济神州终止欧司珀利单抗肺癌3期临床试验

时代财经
03 Apr

本文来源:时代财经4月3日,百济神州宣布终止TIGIT抗体BGB-A1217(欧司珀利单抗)作为肺癌潜在治疗方法的临床开发项目。百济神州表示,依据预先计划的无效性分析结果,独立数据监查委员会建议终止正在进行的3期AdvanTIG-302试验(NCTO4746924)。试验的总体有效性和安全性数据评估表明,该研究或难以达到总生存期主要终点。但同时,未发现新的安全信号。经慎重考虑,公司决定终止该试验。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10